Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Phase 4. How many must suffer to pave the linings? When anavex has safe and proved drug available now?
How hateful the crews that say they care about human beings suffering dementia..
You don’t give a shit
Can you imagine the poor bastards that listened to Corey Renauer of motley fool when he said sell Anavex and buy Biogen a few years back?
Can they sue anyone?
What a cruel and twisted effort that was
All the resources these pumpers stole from legitimate chances to save people with dementia..
How much quicker Anavex and others could have moved without this blockaded fraud in their way..
Oxygen and money hole from hell
Thought they were getting bought out today?
What’s worse is
They knew who anavex was and blew up a chance at a deep relationship through what appears to be a poorly handled MTA ..
Still waiting for Wayne State.. pathetic really..
Arrogance and power smell worse than week old sub Saharan carrion..
Another pump and dump, this time on approval of their drug of all things! Wow, when even approval doesnt work there is some real bad mojo working against you. 3rd or 4 rth cycle of 20 billion that has come and gone. The HFs that own BIIB are making a killing, no pun intended!
$BIIB NEWS!!!! Fasten your SEATBELTS!???????
https://finance.yahoo.com/news/biogen-plans-initiate-phase-3b-113000162.html
Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on
https://www.accesswire.com/viewarticle.aspx?id=663682
Laughable, the pps is one step away from giving up all the fake gains from the announcement of Fda approval for their drug which is still not shown to be efficacious and can be highly toxic for patients including but not limited to death.
OAN Im a little surprised that ihub only allows investors to go back 1 year on the charting….. what gives? Those that forget history are more likely to repeat it. Case in point, I was trying to go back 5 years and look at how Biogen has been overhyped now 3 times for the very close to the exact same amount and has given it all back 2 of the 3 and soon to be 3 for 3 times.
Just an observation.
Pps down $120+ after pumping their bad meds which have no efficacy. Eisai has to break away or go down with the liars. Japanese dont like the bad rep.
STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
By Ed Silverman
The 15-to-0 vote on the Alzheimer's drug Aduhelm amounted to a rebuke of both Biogen and the Food and Drug Administration.
Biogen's Aduhelm stumbles at the starting blocks.
https://endpts.com/major-health-systems-refuse-to-administer-aduhelm-as-top-fda-leaders-meet-behind-closed-doors-to-talk-with-payers/
$BIIB WEEEEEEEEE!!
Hi Mrplmer
This company's lack of evidence for it's drug' safety and effectiveness should plunge the stock to nothing I wonder what s keeping it on the 300 hundreds. Everyday's bad news around then and it keeps going up ?
It doesntcome close to Anavex results.
CLOSED EXTREMELY BULLISH INTO close and afterhours. I wouldnt wanna be a short tomorrow.
Listen to a $BIIB patient who's A DOCTOR! MUST WATCH VIDEO. DRUG WORKS! Poor shorts lost their ONLY ammo to bash it. Their KEY bash has expired, now they're reaching for anything. $BIIB can run for a full week+ shorts will lose houses here. Will run $600+.
https://t.co/1xX3cNoMCk
Down 100 pts since they released the dog. FDA needs to redeem themselves from passing on this POS onto the public.
This is a POS. Puts lipstick on pigs and makes drugs that cause brain bleeds.
CBD...
I am not a short seller and hold no short position in this stock..I have no idea what your background is..I am a healthcare professional an MD with a interest in the history of medicine..
The history of medicine was framed nicely by an old professor of mine..
"In medicine the questions don't change only the answers."
Medical science has advanced by errors and misconceptions which continue until this very day, Ambrose Pare was a French "Barber Surgeon" in the middle ages..In his time gunshot wounds of the legs were treated by immersing the amputation stump in boiling oil..The rationale was not (as some of my comrade surgeons imagine) to stop the bleeding..Bleeding from the major leg vessels required tying off the vessels then as is still the case. The boiling oil emersion was done because the thinking in those days that gun powder was toxic and cause tetanus and gangrene. The oil imersion was done after the vessels were ligate and the bleeding stopped. Pare was fairly busy one day and performed 21 amputations. Later he was told they had no available boiling oil. Pare went to bed that night with a heavy heart.he was convinced all his patients would be dead in the morning. To his surprise he found his patients were doing better than usual, Usual being temperatures of 105 degrees.. He thought it was a miracle..
In 1934 the Nobel Prize in medicine was awarded to Minot and Murphy for discovering the treatment of Pernicious Anemia (rampant in the early 20thcentury). Minot and Murphy were awarded the prize by identifying Folic Acid as the deficiency in PA...Turns out Folic Acid deficiency was not the cause of PA, Later on William Castle(one of my professors) proved the true cause was Vit B12...Castle never got the Nobel Prize. These stories are rampant in the history of medicine...Yes we see tangles in AD..but what do they mean and how does it work?...
AD is a disease relating to aging..To my way of thinking most every condition seen in aging is related to the degree of systemic inflammation..The higher your basal inflammatory levels are, the faster you age and I do not see AZ as an outlier..Want to slow down AD..cut down on your systemic inflammation.
":>) JL
Cbd...
Quote..." The causes are known...Check Anavex studies and chromatin structures.."
Take it up with Eli Lilly
":>) JL
The causes are known
Check Anavex studies and chromatin structures
That was easy good return Thank you. ?????
Thanks for posting...
As Eli Lilly states in its AZD page..The causes and cures of AZD are not known at the present time..I think this is an accurate statement..I think the FDA approval of the Biogen drug is a farce...I don't wish to pee in the punchbowl but the idea of a drug with an estimated annual cost per patient of $56K and no proven efficacy should be investigated...
AZD is a degenerative disease...a disease of aging..most of these disorders are related to inflammation..AZD has ties to CVD which is another manifestation of chronic inflammation..As we know there is a hereditary overlap in all these diseases in terms of their age of onset..Which is also effected by lifestyle factors,,,such as diet, stress and enviromental toxins..All factors which effect longevity...Not everyone has a basal body temperature of 98.6* F...If your resting temp is 99.6* F Then like a roast in the oven the higher the temperature the faster the roast cooks. Same thing with pulse rates...In mammals there is a law that says the faster the pulse rate the shorter the lifespan...and there are no exceptions..Just check your dog's pulse rate..
In my own case. I just turned 80...And I can tell my memory is nowhere near as good at it use to be..I go by the "Jeopardy" test..At age fifty there would be only two or three contestants a year on Jeopardy that could beat beat me...Know almost everyone who wins a contest easily trounces me..It's not that I can not dredge up the answers over a period of time in a lot of cases...It's just there is a long delay period before the answer.
Want to avoid AZD...I don't think Biogens $56 drug is going to help you and its not going to help the cost of medicine in the USA. Watch your lifestyle don't smoke and cut down on your food intake and fast acting carbs. Take Vascepa..(I don't own any shares at present..and watch Jeopardy. Exercise for the mind..
":>) JL
Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision
By Andrew Joseph June 10, 2021
A third member of a Food and Drug Administration expert panel has resigned over the agency’s contentious approval of an Alzheimer’s therapy this week, a sign of a growing backlash over the decision.
In a letter to acting FDA Commissioner Janet Woodcock on Thursday, Aaron Kesselheim, who had served on the FDA’s advisory committee for nervous system therapies since 2015, wrote that the approval of Biogen’s Aduhelm “was probably the worst drug approval decision in recent U.S. history.”
“It is clear to me that FDA is not presently capable of adequately integrating the Committee’s scientific recommendations into its approval decisions,” wrote Kesselheim, the director of Brigham and Women’s Hospital’s Program on Regulation, Therapeutics, and Law. He also cited the FDA’s decision to approve Sarepta Therapeutics’ eteplirsen for Duchenne muscular dystrophy in 2016 over the recommendation of the advisory committee in his decision to quit.
Kesselheim’s resignation follows those of neurologist David Knopman of the Mayo Clinic and neurologist Joel Perlmutter of Washington University in St. Louis. Perlmutter wrote in an email to STAT Tuesday his decision to quit the panel was “due to this ruling by the FDA without further discussion with our advisory committee.”
Knopman, whose resignation was first reported Wednesday by Business Insider, was recused from the aducanumab panel because he had been a trial investigator.
But during the panel’s November hearing on the therapy, 10 of the 11 members voted that there was not enough evidence to show Aduhelm, also known as aducanumab, could slow cognitive decline, recommending against its approval. The 11th voted “uncertain.”
Related: Biogen, FDA at odds over timing of crucial confirmatory trial of Alzheimer’s drug
On Monday, however, the FDA granted Aduhelm an accelerated approval based on the drug’s ability to clear toxic protein plaques in patients’ brains — a regulatory route that FDA officials told the advisory committee in November was not being considered. In explaining the approval, the FDA acknowledged Aduhelm had not demonstrated a clear clinical benefit in terms of slowing disease progression, but argued that by removing the plaques, Aduhelm “is reasonably likely to predict a clinical benefit to patients.”
The FDA also told the chair of the panel Monday that “further discussions” within the agency after the panel’s hearing led to the decision to use the accelerated approval pathway.
The FDA does not have to follow the recommendations of its advisory committees, and researchers have found that it has gone against the votes about 1 in 5 times in recent years. But generally, such overrulings occur when the votes are much closer.
I am in for the WEN thank you. God bless you.
The Structure of Chromatin
I’d rather take a drug that doesn’t add worry to the situation
Hi, JL. I do agree that the FDA’s accelerated approval of Aduhelm based on the premise that clearing amyloid is “reasonably likely” to predict a clinical benefit was a serious overstep.
It’s now going to be much harder to conduct illuminating clinical trials of other AD drug candidates. Few patients will want to enroll in a trial with a placebo arm, and a head-to-head non-inferiority study of a new agent versus Aduhelm wouldn’t really demonstrate anything even if the trial met its endpoints.
Roy....
You know better than anyone that the road to therapeutic Nirvana is paved with land mines...The role of Beta amyloid in the pathogeneses of Alzheimer's Dementia has never been elucidated, and remains one of the great mysteries of clinical medicine..
There exists oblique evidence that suggest that dementia is not created by focal disruption...Multiple Sclerosis is an auto immune disease that results in focal areas of neural loss both above and below the Foramen Magnum...Although MS patients can develop cognitive issues in most cases this is not the impressive aspect of the condition like dementia is in AZ..
If Beta A was the prime cause it would have to function by creating focal disruptions (like MS does)..Most AZ cases begin with personality changes..
Interestingly...Jealousy is a frequent prodrome..
Finally AZ is a disease of aging...And those of you are are veterans of the Vascepa wars know and understand the ravages of aging are principally the effects of inflammation. I would bet AZ is no exception to the rule...Why should it be...
In would like to see a a race between Vascepa and the BIIB drug and would bet heavy money on Vascepa...
Hope all is well
":>)JL
I guess if it works for Joe, the FDA said it works for everyone.
I wonder if living in a basement is a requirement.
No matter what BIIB! Go for it and produce these Amyloid Busters.
And do not forgot to cut down on the fried food!
Alzheimer!!!! what a great Money Maker!
You got a piece of history there.
Hope it is kept as a lucky decision but you will never know down the road. Some drugs get found with serious side effects after a couple of years and Aducanumab is known with serious side effects already.
Wish I got in this in the morning! Will be watching it tomorrow, should be a fantastic day for swing trading.
BIIB made a lucky decision 14 years ago:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=24682934
That’s where Aduhelm came from.
* * $BIIB Video Chart 06-07-2021 * *
Link to Video - click here to watch the technical chart video
BIIB having a monster session
Talk about a short squeese
the shorts just took another big one up there ass
Approved with a note from FDA!
The note puts a quash on any
Massive profit they were expecting!
Should open with euphoria pump
And fade!
That's my take.
Give it a week.
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
626
|
Created
|
11/17/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=BIIB
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of neurology, oncology, immunology, cardiopulmonary, and hemophilia in the United States and internationally. The company?s marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin?s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Hyponatremia; Daclizumab, a Phase II monoclonal antibody that is being tested in relapsing MS; and Fampridine, an oral compound as a treatment to improve walking ability in people with MS. The company?s products under preclinical stage comprise BIIB014, Ocrelizumab, Neublastin, LINGO, and BART for neurology; Hsp90 Inhibitor, GA101, Anti-IGF-1R, Volociximab, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for immunology; and Long-acting rFactor VIII for hemophilia. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; UCB, S.A.; Swedish Orphan Biovitrum AB; Facet Biotech Corporation; Vernalis plc; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |